Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

The search for an HIV prevention vaccine news


From To
How Natural Killer cells regulate protective HIV antibodies

The finding advances efforts to develop a vaccine that elicits protective HIV antibodies.

01 October 2018
Science Daily
Special antibodies could lead to HIV vaccine

Around one percent of people infected with HIV produce antibodies that block most strains of the virus. These broadly acting antibodies provide the key to developing an effective vaccine against HIV. Researchers have now shown that the genome of the HI virus is a decisive factor in determining which antibodies are formed.

11 September 2018
Science Daily
Vaccines Against H.I.V., Malaria and Tuberculosis Unlikely, Study Says

Unless the $3 billion spent annually on research triples, the world may not be able to invent vaccines or rapid cures for many ills of the poor.

10 September 2018
New York Times
Looking at a 2009 HIV Vaccine Trial to Develop a Future Vaccine

The Campbell Foundation’s latest grant funds research into the RV144 trial in Thailand, which showed 31 percent protection against HIV.

29 August 2018
Will an HIV vaccine that protected two-thirds of monkeys do the same for humans?

The Lancet last Friday published the 52-week results of APPROACH, an HIV vaccine whose 28-week results, reported by last year, were sufficiently impressive for it to

13 July 2018
Gus Cairns
Novel HIV vaccine candidate is safe and induces immune response in healthy adults and monkeys

New research published in The Lancet shows that an experimental HIV-1 vaccine regimen is well-tolerated and generated comparable and robust immune responses against HIV in healthy adults and rhesus monkeys. Moreover, the vaccine candidate protected against infection with an HIV-like virus in monkeys.

09 July 2018
Eurekalert Inf Dis
Abivax releases positive top line data from ABX464-005 phase 2a study in HIV infection

“These findings show, for the first time, that ABX464 has the ability to reduce HIV DNA in both blood and rectal tissue reservoirs,” said Dr Jean-Marc Steens, Chief Medical Officer at ABIVAX. “The longer 12 week duration of treatment with ABX464 was safe and generally well tolerated and supports extended dosing.”

04 July 2018
Abivax press release
HIV vaccine elicits antibodies in animals that neutralize dozens of HIV strains

NIH study results represent major advance for structure-based HIV vaccine design.

05 June 2018
National Institutes of Health (press release)
Healthy competition intensifies 30-year quest for HIV vaccine

By funding two similar projects at once, the EU aims to inspire a sense of friendly competition between them. But the programmes share researchers and conduct complementary work, careful not to duplicate their efforts. Both Prof. Shattock and Prof. Pantaleo say that either European team would be happy if the other found a vaccine that worked.

21 May 2018
Horizon magazine
Inovio HIV Vaccine, Which Generated Near 100% Immune Responses, Sustained Durable Memory Responses Measured One Year After The Start of Clinical Trial

Inovio Pharmaceuticals, Inc. today announced that its HIV vaccine, PENNVAX®-GP, maintained durable and robust immune responses at month 12, a full six months after the last dose in a Phase 1 clinical study. Inovio previously reported that PENNVAX-GP elicited the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine.

16 May 2018
Inovio press release

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.